Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A4 A*24 TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A4 A*24 TCR-T is an autologous T-cell receptor (TCR) engineered T-cell therapy developed by Anocca. It is designed to target the Melanoma-Associated Antigen A4 (MAGE-A4) protein, specifically when presented as a peptide fragment by the Human Leukocyte Antigen (HLA) allele A*24 (HLA-A*24). MAGE-A4 is a cancer-testis antigen frequently overexpressed in various solid tumors but absent in normal adult tissues (except germ cells), making it a highly specific target for immunotherapy. The therapy involves engineering a patient's own T cells to express a high-affinity TCR specific to the MAGE-A4/HLA-A*24 complex, enabling the T cells to recognize and eliminate tumor cells. It is currently being investigated for the treatment of a wide range of cancers.
- Other names
- Anocca MAGE-A4 A*24 TCR-TMAGE-A4 HLA-A*24 TCR-T cell therapy
02
Targets
HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)
Beyond the preview
Go deeper on MAGE-A4 A*24 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A4 A*24 TCR-T.